New granted patents added to Hamlet BioPharma's extensive patent portfolio in cancer and infection
Hamlet BioPharma's extensive patent portfolio comprises 147 granted patents and 33 pending cases. Strategy regarding intellectual property rights, follow up and extension of filed cases and patenting of new discoveries is overseen by the internationally established legal firm Greaves-Brewster LLP, who have advised Hamlet BioPharma since the start.
We are delighted to announce the recent grant of three patents in the company's portfolio.
- The Hamlet Mixing Method patent (CN 110650746) was granted in China on December 31st 2024.
This patent to protects an improved method for the production of HAMLET complexes, especially Alpha1H for clinical trials.
2. The Pol II inhibitors patent (IN 558357) was granted in India on January 21st 2025.
3. The Pol II inhibitors patent (AU 2017344453) was granted in Australia on March 6th 2025.
The Pol II inhibitors patents protect the molecule NlpD, which has shown strong therapeutic effects against bacterial infections in animal models. This protein inhibits excessive inflammation and accelerates bacterial clearance.
For more information, please contact
Catharina Svanborg, CEO and founder, +46 709 42 65 49
Ines Ambite, senior scientist, Lund University +46-762 08 89 58